HIV and tobacco use cessatio

Phase 4

• Conditions: HIV/AIDS

• Registration Number: PACTR202211868634078
• Lead Sponsor: niversity of California San Francisco

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 580

Inclusion Criteria

Clinical Component (Randomized Control trial):
-age =18 years
-HIV-seropositive
-on or initiating ART
-not planning to move or travel within 12 weeks following entry in the study
-Tobacco inclusion criteria: current tobacco users, i.e. used tobacco in the past 7 days; for smokers, smoked at least 100 cigarettes in lifetime, and at least 5 cigarettes per day, verified by expired Carbon Monoxide (CO)= 5-6 parts per million (ppm).
-access to mobile phone for phone contact (and on intensive intervention also for text follow up visit)
Additional inclusion criteria for intensive intervention only:
-able to read or be read for the SMS messages

Exclusion Criteria

Clinical Component:
-age < 18 years
-HIV-seronegative
-unable to provide informed consent
-unwilling to be contacted by clinic for follow up
-Opioid users (who may be receiving Bupropion as part of their treatment)
Additional exclusion criteria for intensive intervention only:
-Myocardial Infarction in the 2 weeks prior to enrolling in the study
-Pregnant (as NRT and Bupropion might be contraindicated).
-We will also exclude patients for whom Bupropion is contraindicated (e.g. history of seizures, recent use of MAO inhibitors, breastfeeding, and whose ART protocol present, as per prescription guidance, contraindications).
-For those who share phones, prior disclosure of HIV status to the phone owner will be required to prevent inadvertent disclosure

Study & Design

• Study Type: Interventional
• Study Design: Not specified